BIO-RAD LABORATORIES, INC. (BIO) earnings date, results and what the price requires
NYSE · SEC CIK 0000012208 · SEC filings checked Oct 16, 2026
Previous results (SEC filings)
| Quarter ended | Reported | Revenue | Net income | Diluted EPS | Source |
|---|---|---|---|---|---|
| Jun 30, 2026 | Aug 4, 2026 | $651.0M | $371.4M | $13.85 | Filing |
| Mar 31, 2026 | Apr 30, 2026 | $592.1M | $-527.1M | $-19.55 | Filing |
| Dec 31, 2025 | Feb 12, 2026 | $693.2M | $720.0M | $26.59 | Filing |
| Sep 30, 2025 | Oct 29, 2025 | $653.0M | $-341.9M | $-12.70 | Filing |
| Jun 30, 2025 | Jul 31, 2025 | $651.6M | $317.8M | $11.67 | Filing |
| Mar 31, 2025 | May 1, 2025 | $585.4M | $64.0M | $2.29 | Filing |
| Dec 31, 2024 | Feb 13, 2025 | $667.5M | $-715.8M | $-25.57 | Filing |
| Sep 30, 2024 | Oct 30, 2024 | $649.7M | $653.2M | $23.34 | Filing |
What would BIO-RAD LABORATORIES, INC. have to report for its valuation to change?
At $364.82, with a 9.0% required return and a 18× earnings multiple in 5 years, earnings per share must grow about 30.7% a year, to $31.18. On that path the next quarter needs diluted EPS near $-16.59, against $-12.70 in the quarter ended Sep 30, 2025.
Compare buying at the last close now with waiting for results: if the report moves the growth the price requires, the entry price you would accept changes with it.
| Result | Original | Yours |
|---|---|---|
| Required EPS growth / year | 30.7% | 30.7% |
| EPS needed in final year | $31.18 | $31.18 |
Changed: nothing yet. Model: EPS × (1+g)^years × final P/E, discounted at the required return, equals today's price. Inputs: SEC diluted EPS and the dated close above.
Prepare for earnings across my investments — $399/month
Keep working models for the companies you follow, compare your expectations with reported results, and review what changes your investment decision. BIO goes in with your buy-or-wait comparison and assumptions preserved.
Figures come from SEC EDGAR XBRL filings. Dates marked "estimated" are calculated from the company's past results filings and are not confirmed. Not investment advice.